QINA for Cancer Patients


Cancer not only affects the individual, but has a distressing effect on the surrounding family and friends who feel completely helpless to act. As a coping mechanism, the psychology of the cancer patient goes through a series of mind altering processes that helps them prepare for the possible consequences of this debilitating disease. The scope of the Qina clinical trials focused on two areas.
(1) To ensure the quality of life of the cancer patient and
(2) To increase the duration of life.

What can Qina offer you as a Cancer patient:

We have already discussed the effects on the key cell of the immune system the Macrophage. Macrophages are believed to help cancer cells proliferate. They are attracted to oxygen-starved (hypoxia) tumour cells and promote chronic inflammation. Inflammatory compounds such as Tumor necrosis factor (TNF) released by the macrophage activates the gene switch nuclear factor-kappa B.
NF-kB then enters the nucleus of a tumour cell and turns on production of proteins that stop apoptosis and promote cell proliferation and inflammation. It is known through clinical studies that Qina possesses anti inflammatory properties by the activation and modulation of the Macrophage. The resulting conclusion is that Qina provides, amongst other beneficial factors, an improved Quality of Life.

The standard medical protocol in treating cancer includes some of the most toxic therapies known to man. The collateral side effects can be as debilitating as the disease itself. Qina offers both the patient and the surrounding family and friends the power to provide a solution to "quality of life" as this aspect is generally ignored by physicians.

Qina does not profess to be a cure for cancer, however the following statements have been proven in large clinical trials.
Qina provides a regression of the symptoms, which include a lessening of pain, improved appetite, weight gained, increased cognitive function and an overall feeling of wellness returns. There is also evidence of the regression of the lesion itself, thus making the disease's prognosis, look considerably better.

The largest difficulty of antineoplastic chemotherapy, is drug resistance. The performance of Qina on these patients promoted an adhesion to the treatment for the improvement of life quality, with a decrease in side effects and the absence of myelosuppression provoked by the chemotherapy drugs, allowing adherence to the treatment and for the continuity of antineoplastic effects, to be maintained.

What does this mean?

Qina's consistent performance demonstrated constant weight gain, and avoidance of loss of corporal mass, which are characteristics of the disease and the aggressive therapy, a return of full cognitive function where the accomplishment of physical activities such as walking, leisure activities and even the return, even if partial, to productive activities were made possible.

Patients treated with Qina, in conjunction with conventional therapies presented a decrease in pain complaints, improvement in appetite and cognitive function were noticed almost immediately after the start of the treatment, with continuous constant improvement over time. There is a noticeable reduction in nausea and vomiting and a general feeling of well being. The possibility of physical activities were a result in the improvement of life quality and it provided an improvement of observed self-esteem during the treatment.


The performance progression shows with clarity that a medication without toxicity and/or collateral effects, acting on the body defences, becomes indispensable to the modern therapeutic arsenal. In most of the patients, there was a significant decrease of tumour volumes, after the therapy with Qina. This fact made it possible to discuss the option of re-instituting invasive treatments or, surgery or even restarting the cycle of chemotherapy, which had been stopped.

Another verified fact is the high adhesion index to the treatment with Qina where the attending patients went in search of the medication so that they could remain on the treatment after the study. Even in those where there was partial or total tumor mass resolution, the interest of carrying on taking the medication was unanimous.